Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves' Ophthalmopathy.
DNA methylation
epigenetics
graves’ ophthalmopathy
orbital fibroblast
proteomics
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
10
2020
accepted:
21
12
2020
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
27
5
2021
Statut:
epublish
Résumé
Graves' ophthalmopathy (GO) is a frequent extrathyroidal complication of Graves' hyperthyroidism. Orbital fibroblasts contribute to both orbital tissue inflammation and remodeling in GO, and as such are crucial cellular elements in active GO and inactive GO. However, so far it is largely unknown whether GO disease progression is associated with functional reprogramming of the orbital fibroblast effector function. Therefore, the aim of this study was to compare both the proteome and global DNA methylation patterns between orbital fibroblasts isolated from active GO, inactive GO and healthy controls. Orbital fibroblasts from inactive GO (n=5), active GO (n=4) and controls (n=5) were cultured and total protein and DNA was isolated. Labelled and fractionated proteins were analyzed with a liquid chromatography tandem-mass spectrometer (LC-MS/MS). Data are available Orbital fibroblasts from active GO displayed overexpression of proteins that are typically involved in inflammation, cellular proliferation, hyaluronan synthesis and adipogenesis, while various proteins associated with extracellular matrix (ECM) biology and fibrotic disease, were typically overexpressed in orbital fibroblasts from inactive GO. Moreover, orbital fibroblasts from active GO displayed hypermethylation of genes that linked to inflammation and hypomethylated genes that linked to adipogenesis and autoimmunity. Further analysis revealed networks that contained molecules to which both hypermethylated and hypomethylated genes were linked, including NF-κB, ERK1/2, Alp, RNA polymerase II, Akt and IFNα. In addition, NF-κB, Akt and IFNα were also identified in networks that were derived from the differentially expressed proteins. Generally, poor correlation between protein expression, DNA methylation and mRNA expression was observed. Both the proteomics and DNA methylation data support that orbital fibroblasts from active GO are involved in inflammation, adipogenesis, and glycosaminoglycan production, while orbital fibroblasts from inactive disease are more skewed towards an active role in extracellular matrix remodeling. This switch in orbital fibroblast effector function may have therapeutic implications and further studies into the underlying mechanism are thus warranted.
Sections du résumé
Background
Graves' ophthalmopathy (GO) is a frequent extrathyroidal complication of Graves' hyperthyroidism. Orbital fibroblasts contribute to both orbital tissue inflammation and remodeling in GO, and as such are crucial cellular elements in active GO and inactive GO. However, so far it is largely unknown whether GO disease progression is associated with functional reprogramming of the orbital fibroblast effector function. Therefore, the aim of this study was to compare both the proteome and global DNA methylation patterns between orbital fibroblasts isolated from active GO, inactive GO and healthy controls.
Methods
Orbital fibroblasts from inactive GO (n=5), active GO (n=4) and controls (n=5) were cultured and total protein and DNA was isolated. Labelled and fractionated proteins were analyzed with a liquid chromatography tandem-mass spectrometer (LC-MS/MS). Data are available
Results
Orbital fibroblasts from active GO displayed overexpression of proteins that are typically involved in inflammation, cellular proliferation, hyaluronan synthesis and adipogenesis, while various proteins associated with extracellular matrix (ECM) biology and fibrotic disease, were typically overexpressed in orbital fibroblasts from inactive GO. Moreover, orbital fibroblasts from active GO displayed hypermethylation of genes that linked to inflammation and hypomethylated genes that linked to adipogenesis and autoimmunity. Further analysis revealed networks that contained molecules to which both hypermethylated and hypomethylated genes were linked, including NF-κB, ERK1/2, Alp, RNA polymerase II, Akt and IFNα. In addition, NF-κB, Akt and IFNα were also identified in networks that were derived from the differentially expressed proteins. Generally, poor correlation between protein expression, DNA methylation and mRNA expression was observed.
Conclusions
Both the proteomics and DNA methylation data support that orbital fibroblasts from active GO are involved in inflammation, adipogenesis, and glycosaminoglycan production, while orbital fibroblasts from inactive disease are more skewed towards an active role in extracellular matrix remodeling. This switch in orbital fibroblast effector function may have therapeutic implications and further studies into the underlying mechanism are thus warranted.
Identifiants
pubmed: 33658982
doi: 10.3389/fendo.2020.619989
pmc: PMC7919747
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
619989Informations de copyright
Copyright © 2021 Virakul, Somparn, Pisitkun, van der Spek, Dalm, Paridaens, van Hagen, Hirankarn, Palaga and Dik.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Invest Dermatol. 2016 Jan;136(1):74-83
pubmed: 26763426
Am J Pathol. 2005 Mar;166(3):695-708
pubmed: 15743782
Curr Eye Res. 2013 Jun;38(6):699-706
pubmed: 23281820
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
J Biol Chem. 1996 Oct 25;271(43):26884-91
pubmed: 8900172
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5457-64
pubmed: 26284551
Cancer Sci. 2014 Mar;105(3):265-71
pubmed: 24418124
Mol Biol Cell. 2011 Oct;22(19):3671-83
pubmed: 21832155
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4027-34
pubmed: 27494344
Gastroenterology. 1998 Jan;114(1):139-52
pubmed: 9428228
Nat Commun. 2015 Dec 15;6:10204
pubmed: 26667266
Eur J Endocrinol. 2017 Apr;176(4):481-488
pubmed: 28077500
Matrix Biol. 2014 Apr;35:8-13
pubmed: 24134926
J Immunol. 2003 Jun 15;170(12):6348-54
pubmed: 12794168
Thyroid. 1998 May;8(5):429-32
pubmed: 9623737
Arthritis Rheum. 2009 May;60(5):1519-29
pubmed: 19404935
Biochem Biophys Res Commun. 2007 Apr 13;355(3):745-50
pubmed: 17320047
Cell Mol Life Sci. 2016 Mar;73(6):1145-57
pubmed: 26681260
Front Immunol. 2018 Feb 12;9:98
pubmed: 29483906
Curr Genomics. 2007 Nov;8(7):453-65
pubmed: 19412418
Thyroid. 2008 Sep;18(9):983-8
pubmed: 18788919
Nat Genet. 2012 Nov;44(11):1236-42
pubmed: 23064414
Eur Respir Rev. 2017 May 17;26(144):
pubmed: 28515040
Lab Invest. 2010 May;90(5):739-52
pubmed: 20195245
Cytokine. 2006 Aug;35(3-4):109-14
pubmed: 17008110
Invest Ophthalmol Vis Sci. 2009 May;50(5):2262-8
pubmed: 19117935
J Endocrinol Invest. 2016 Jan;39(1):63-72
pubmed: 26062519
Thyroid. 2019 Mar;29(3):395-404
pubmed: 30724135
Eur Thyroid J. 2014 Dec;3(4):217-26
pubmed: 25759797
Genome Res. 2011 Jul;21(7):1074-86
pubmed: 21628449
Oncogene. 1999 Jan 14;18(2):385-96
pubmed: 9927195
Annu Rev Nutr. 2004;24:277-98
pubmed: 15189122
Lab Invest. 1991 Jun;64(6):791-8
pubmed: 2046331
J Immunol. 2008 Sep 15;181(6):4397-405
pubmed: 18768899
J Endocrinol Invest. 2004 Mar;27(3):265-71
pubmed: 15165003
Thorax. 2015 Nov;70(11):1022-32
pubmed: 26359372
Endocrinology. 2017 Oct 1;158(10):3676-3683
pubmed: 28938449
Mol Cell Endocrinol. 2016 Sep 15;433:94-104
pubmed: 27267669
Thyroid. 2008 Dec;18(12):1291-6
pubmed: 18976167
Sci Rep. 2018 Jan 17;8(1):917
pubmed: 29343699
Front Physiol. 2017 Feb 13;8:45
pubmed: 28243204
Int J Mol Sci. 2019 Jun 01;20(11):
pubmed: 31159366
Nat Rev Immunol. 2011 Jun;11(6):427-35
pubmed: 21597472
Mol Cell Endocrinol. 2017 May 5;446:1-11
pubmed: 28087387
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1002-7
pubmed: 19797221
Front Immunol. 2019 Feb 04;10:85
pubmed: 30778349
Mol Aspects Med. 2017 Apr;54:89-102
pubmed: 27720780
Mol Cancer. 2016 Jan 22;15:9
pubmed: 26801246
Mol Immunol. 2011 Dec;49(3):518-26
pubmed: 22036612
Oncol Rep. 2019 Apr;41(4):2137-2147
pubmed: 30816499
PLoS One. 2014 Sep 12;9(9):e107055
pubmed: 25215577
J Clin Endocrinol Metab. 2011 Nov;96(11):E1727-36
pubmed: 21917865
Exp Eye Res. 2016 Jan;142:83-91
pubmed: 26675405
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3091-8
pubmed: 19234339
N Engl J Med. 2010 Feb 25;362(8):726-38
pubmed: 20181974
Front Pharmacol. 2014 May 27;5:123
pubmed: 24904424
Thyroid. 2008 Mar;18(3):333-46
pubmed: 18341379
Genes Dev. 2004 Oct 1;18(19):2315-35
pubmed: 15466484
Clin Endocrinol (Oxf). 2003 Mar;58(3):280-7
pubmed: 12608932
Cells. 2018 Sep 07;7(9):
pubmed: 30205516
Am J Respir Crit Care Med. 1995 Jun;151(6):1956-64
pubmed: 7767545
Invest Ophthalmol Vis Sci. 2012 Nov 21;53(12):7746-53
pubmed: 23092922
J Clin Endocrinol Metab. 2019 Feb 1;104(2):581-594
pubmed: 30445529
J Clin Endocrinol Metab. 2015 Dec;100(12):E1523-30
pubmed: 26451909
J Clin Endocrinol Metab. 2014 Sep;99(9):3363-72
pubmed: 24840811
J Clin Endocrinol Metab. 2014 Jul;99(7):E1236-44
pubmed: 24708100
Ann Rheum Dis. 2015 Aug;74(8):1612-20
pubmed: 24812288
Cancer Cell. 2014 Oct 13;26(4):577-90
pubmed: 25263941
Epigenetics. 2014 Aug;9(8):1061-70
pubmed: 24802768
Gene. 2017 Dec 15;636:87-95
pubmed: 28919164
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6438-47
pubmed: 26444724
Expert Rev Mol Med. 2011 Aug 23;13:e27
pubmed: 21861939
EMBO J. 1992 Dec;11(12):4281-90
pubmed: 1425570
Cell Rep. 2013 Feb 21;3(2):386-400
pubmed: 23403290
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):281-9
pubmed: 22632365
Thyroid. 2003 Sep;13(9):845-50
pubmed: 14588098
Sci Rep. 2018 Jun 12;8(1):8957
pubmed: 29895898
Nat Med. 2012 Jul 06;18(7):1028-40
pubmed: 22772564
Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2777-87
pubmed: 23982774
Biosci Rep. 2017 Jan 17;37(1):
pubmed: 27986864
FEBS J. 2009 Oct;276(19):5537-46
pubmed: 19702828